For the first time, scientists can now leverage the reproducibility of ioCells to study how the four major CNS cell types interact and contribute to neurological diseases. This enables more precise research and opens new doors for developing effective treatments.

• Human astrocytes are key to developing effective in-vitro models of the central nervous system (CNS), enabling the study and testing of new treatments for neurological and neurodegenerative diseases.
• ioAstrocytes, the newest addition to bit.bio’s ioCells CNS toolkit, are highly characterized and functional, offering consistent results and addressing the variability issues associated with primary astrocytes.
• Designed for ease of use with open-source media and protocols, ioAstrocytes can be co-cultured with other brain cells, including bit.bio’s ioCells range, allowing researchers to model brain complexity and gain valuable insights into disease mechanisms and treatments.

bit.bio, the company coding human cells for novel cures and a pioneer in the field of synthetic biology, today announces the launch of ioAstrocytes. This new addition to bit.bio’s ioCells portfolio creates an unparalleled toolkit for disease research that addresses the challenges of data reproducibility and enables accelerated therapeutic development.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240619695116/en/

bit.bio launches ioAstrocytes, advancing how scientists can model the human brain (Photo: Business Wire)

ioCells, iPSC-derived cells for research and drug discovery, are manufactured using bit.bio's deterministic programming technology, opti-ox, and are considered best in class for their functionality, consistency, and scalability. With 18 launches to date in 2024, bit.bio’s ioCells portfolio comprises 37 products, including ioWild Type Cells, ioDisease Model Cells and ioCRISPR-Ready Cells.

Astrocytes are a type of glial cell in the brain involved in a wide range of processes, including neural signalling, homeostasis maintenance, and immune response regulation. The significance of astrocytes for effectively modelling the human brain is frequently underestimated. Growing evidence highlights the important role of astrocytes in CNS conditions, such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, epilepsy, pain disorders, and neuropsychiatric conditions. With the introduction of ioAstrocytes, scientists now have access to defined, consistent, and functional human astrocytes optimised for co-culture with other CNS cell types.

"We are excited to expand the universe of ioCells with ioAstrocytes and offer researchers worldwide access to the major cell types of the human brain,” said Mark Kotter, Founder and CEO of bit.bio. "Much like building blocks, scientists can combine different CNS cell types with or without disease-specific mutations to explore their interactions. We look forward to seeing how the neuroscience community will leverage this powerful toolkit to further our understanding of the CNS and develop much needed therapies for neurological conditions.”

ioAstrocytes are highly defined, consistent, and functional human astrocytes, optimised for co-culture with other CNS cell types. They display stellate morphology, express key markers, and perform essential astrocyte functions such as phagocytosis, secretion of cytokines, and modulation of neuronal activity when co-cultured with CNS cells.

“ioAstrocytes represent a significant addition to bit.bio's growing ioCells portfolio, enabling researchers to enhance in-vitro CNS models and accelerate discoveries,” said Farah Patell-Socha, Vice President of Research Products at bit.bio. "By providing highly consistent cells with essential functional properties of human astrocytes, we’re unlocking novel ways for advancing neuroinflammation research, conducting in-depth neural network studies, and performing screening and toxicity assessments for potential therapeutics."

For more information or to purchase bit.bio’s ioAstrocytes, please visit the Product page.

About bit.bio

bit.bio, a synthetic biology company, is democratising human cells to advance biomedical research (SDG9) and enable transformative treatments (SDG3). With Nobel Prize-winning science underpinning our understanding of cell identity as defined by unique combinations of transcription factors, our deterministic cell programming technology, opti-ox, enables conversion of induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step. This is achieved within days and at industrial scale, while maintaining exceptional purity and consistency. We are creating highly differentiated human cell products for research and drug discovery (ioCells) and cell therapy (txCells). Our growing commercial ioCells portfolio comprises ioWild Type Cells, ioDisease Model Cells and ioCRISPR-Ready Cells. Our cell therapy pipeline is currently focused on metabolism and endocrinology, immunology and neurology therapeutic areas. Our lead candidate, bbHEP01 (encapsulated allogeneic txHepatocytes), is in development for acute liver diseases. Additionally, we are collaborating with BlueRock Therapeutics (a wholly owned independently operated subsidiary of Bayer AG) on regulatory T cell (Treg)-based cell therapies.

Since spinning out from the University of Cambridge and launching in 2016, we have raised approximately $200m from leading investors, including Arch Venture, Blueyard Capital, Charles River Laboratories, Foresite Capital, Milky Way, National Resilience, and Tencent.

For more information, please visit: www.bit.bio

For information on bit.bio’s trademarks, visit www.bit.bio/trademarks LinkedIn: https://www.linkedin.com/company/bitbioltd/

View source version on businesswire.com: https://www.businesswire.com/news/home/20240619695116/en/